

**Wanbury Limited**

Regd. Office : BSEL Tech Park, 8-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
Fax : +91-22-6794 2111/333
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

30th July, 2026

BSE Limited PJ. Towers, Dalal Street Mumbai- 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Script Code: WANBURY
---	---

Dear Sir/Madam

Sub.: Fully Compliant - No DMF deficiency letter received from the office of USFDA for multiple ANDAs

As per Regulation 30 of SEBI LODR, Wanbury Limited recently received "No DMF deficiency letter" from the office of USFDA (US Food and Drug Administration) for multiple ANDAs (Abbreviated New Drug Applications) with Metformin HCl API source of Wanbury for different formulations.

As previously informed, Wanbury expanded business opportunities in South Korea for one more API by filing the DMF. Wanbury is committed for supply of best APIs to the new market for well-being of human being.

This is for your information and record.

Thanking you.

**Yours faithfully,
For Wanbury Ltd**



**Jitendra J. Gandhi
Company Secretary**

